Month: December 2013

Phase 3 study results show dry eye therapy safe but ineffective

Results from a 24 week placebo-controlled phase 3 study recently released by OphthaliX showed that the company’s licensed drug, CF101, for the treatment of dry eye, while well-tolerated, met neither primary nor secondary efficacy endpoints, according to a company press release.The study included 237 patients with moderate-to-severe dry eye syndrome randomized to receive two oral doses of CF101, an A3 adenosine receptor agonist (0.1 mg or 1.0 mg), or a placebo, for a period of 24 weeks, the release said.

Topical antibiotics treat smaller corneal grafts infected with multi-drug resistant Pseudomonas aeruginosa

Corneal grafts infected with multi-drug resistant Pseudomonas aeruginosa were more successfully treated with topical antibiotics when the corneal graft infiltrate was small, according to a study. Of 38 patients with multi-drug resistant Pseudomonas aeruginosa infection, 31 were initially treated with combined cefazolin 5% and ciprofloxacin 0.3%, six were initially treated with colistin 0.19%, and one patient was initially treated with impenem 1%. After 2 weeks, infection resolved in nine patients and partially resolved in six.

BLOG: Tiny miracles

It’s the Christmas season, and it’s gotten me to thinking about what we all do as doctors and the effect our care has on our patients and their families. How many times have you had a patient, particularly a dry eye patient, describe what you have done for them as a miracle? Kind of humbling in a way, isn’t it? We make a diagnosis at the slit lamp, send off a few electrons from the EMR that get translated into a drop of some sort and someone calls it a (Read more...)